indication directory

Solid Tumors clinical trial intelligence

Trials are included only when the source condition or controlled indication mapping directly matches this disease area. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

indication

Association rule

source condition

NCT07246863

Source recordAI-normalized

Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

AI analysis

Indication: Metastatic Non-Squamous Non-Small Cell Lung Cancer

Modality: monoclonal antibody

Target: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel

Sponsor: CatalYm GmbH

Source URL: ClinicalTrials.gov

Source updated: Jun 09, 2026

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Adult Solid Tumor

View original source fields

Condition raw: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

Condition normalized: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

Modality raw: monoclonal antibody

Modality normalized: monoclonal antibody

Target raw: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel

Target normalized: Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel

Open report

NCT06131398

Source recordAI-normalized

A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.

AI analysis

Indication: Advanced Solid Tumors

Modality: small molecule

Target: AMG 355, Pembrolizumab

Sponsor: Amgen

Source URL: ClinicalTrials.gov

Source updated: May 28, 2026

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Advanced Solid Tumors

View original source fields

Condition raw: Advanced Solid Tumors

Condition normalized: Advanced Solid Tumors

Modality raw: small molecule

Modality normalized: small molecule

Target raw: AMG 355, Pembrolizumab

Target normalized: AMG 355, Pembrolizumab

Open report

NCT01288430

Source recordAI-normalized

A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors

This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors. The patients who qualify for the study will receive a once daily dose of the drug taken by mouth and will undergo several tests to measure the drug in the blood and to understand the safety, tolerability and any effect of the drug on the tumor. The antitumor effect of the drug is not known in human.

AI analysis

Indication: Solid Tumors

Modality: small molecule

Target: DS-2248

Sponsor: Daiichi Sankyo

Source URL: ClinicalTrials.gov

Source updated: Oct 05, 2021

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Solid Tumors

View original source fields

Condition raw: Solid Tumors, Non-small Cell Lung Carcinoma

Condition normalized: Solid Tumors, Non-small Cell Lung Carcinoma

Modality raw: small molecule

Modality normalized: small molecule

Target raw: DS-2248

Target normalized: DS-2248

Open report

NCT04589845

Source recordAI-normalized

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

The TAPISTRY study, sponsored by Hoffmann-La Roche, is a global, multicenter, open-label trial evaluating the safety and efficacy of targeted therapies and immunotherapies in patients with unresectable, locally advanced, or metastatic solid tumors. The trial aims to personalize treatment based on genomic profiling, potentially enhancing therapeutic outcomes.

AI analysis

Indication: Solid Tumors

Modality: small molecule

Target: Solid Tumors with specific oncogenic genomic alterations or TMB-high

Sponsor: Hoffmann-La Roche

Source URL: ClinicalTrials.gov

Source updated: May 08, 2026

Ingested: Jun 05, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Solid Tumors

View original source fields

Condition raw: Solid Tumors

Condition normalized: Solid Tumors

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Entrectinib, Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib

Target normalized: Solid Tumors with specific oncogenic genomic alterations or TMB-high

Open report

NCT05389462

Source recordAI-normalized

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

ADC Therapeutics S.A. initiated a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumors, particularly focusing on sarcomas and pancreatic cancer. The study aimed to establish the recommended phase 2 dose and assess the drug's efficacy in combination with gemcitabine.

AI analysis

Indication: Advanced Solid Tumors

Modality: monoclonal antibody

Target: Mipasetamab Uzoptirine (ADCT-601)

Sponsor: ADC Therapeutics S.A.

Source URL: ClinicalTrials.gov

Source updated: May 22, 2025

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Advanced Solid Tumors

View original source fields

Condition raw: Advanced Solid Tumors

Condition normalized: Advanced Solid Tumors

Modality raw: Advanced Solid Tumors

Modality normalized: monoclonal antibody

Target raw: Mipasetamab Uzoptirine (ADCT-601)

Target normalized: Mipasetamab Uzoptirine (ADCT-601)

Open report